CHC

  • About Us
  • News
  • Coming Up
  • Resources
  • Contact Us
  • Search

Digitas: FDA Warning to Novartis Over Facebook Post Contains Upside

August 6, 2010

Read a detailed analysis of the DDMAC warning letter to Novartis about a Facebook posting that did not include appropriately posted warnings and contraindications.

Peter Pitts has more analysis canadian pharmacies online cialis in his blog at

how to remove genital warts

Please read, then come back here to comment.celebrex brand buy no prescription

Posted in General

Post navigation

Europe Beating U.S. Hands Down in Oncology
Associations React to NIH-Proposed Conflict of Interest Rules

Categories

  • CHC News
  • Courts/First Amendment
  • Data Privacy
  • Drug Pricing
  • DTC Advertising
  • General
  • Legislative
  • Off-label Promotion
  • Point of Care
  • Regulatory/FDA
  • Uncategorized
  • Washington Focus

Recent Posts

  • FTC Releases New Staff Paper on Harms to Kids & Teens from Online “Blurred” or Stealth Advertising
  • California AG Investigates Large Employers for CCPA Employee Data Compliance
  • FTC Issues Proposed Rule Identifying 7 Deceptive Marketing Review and Testimonial Practices
  • California Court Issues Order to Delay Enforcement of CPRA Regulations until March 2024
  • FTC Releases First Update to Endorsement Ad Guidelines in a Decade

Tags

4A's ACA ad tax Advertising Coalition CDER chc CMS coalition for healthcare communication conflict of interest Congress COVID-19 data privacy DDMAC drug prices in DTC ads drug pricing DTC DTC advertising DTC advertising FDA FDA Commissioner FDA Draft Guidance FDA enforcement FDA social media free speech gifts to physicians HHS John Kamp Jon Bigelow kamp Kate Rawson legislation litigation off-label off-label communication OPDP OPDP enforcement PhRMA regulation rx data Scott Gottlieb social media sunshine act Untitled Letter Warning Letter Wayne Pines
CHC

Smart Brief
© 2023 Coalition for Healthcare Communication. All rights reserved.